Zhi bo Gai

Dr. Zhi bo Gai


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TGTing Gui
Ting Gui
YLYunlun Li
Yunlun Li
SZShijun Zhang
Shijun Zhang
NZNan Zhang
Nan Zhang
YSYing Sun
Ying Sun
ZGZhi bo Gai
Zhi bo Gai
Regular consumption of n-3 polyunsaturated fatty acids is associated with decreased cardiovascular morbidity and mortality. This study assessed the therapeutic effect of docosahexaenoic acid (DHA) in palmitic acid (PA)-induced cytotoxicity in vitro and in rats fed a high-fat diet (HFD). H9C2 cells and rat primary cardiomyoblasts were exposed to PA or PA + DHA for 24 h. PA-induced lipotoxicity and mitochondrial dysfunction were evaluated by immunostaining, real-time PCR, cardiomyocyte contraction and transmission electron microscopy. The effects of dietary DHA on diabetic cardiomyopathy were evaluated in male Sprague-Dawley rats fed a reference diet rich in DHA, an HFD, or an HFD with added DHA for 16 weeks. Oxidative stress and lipotoxicity in rat heart tissue were assayed by Masson staining, immunohistochemistry, and TUNEL. In vitro studies showed that dietary DHA reduced the occurrence of cardiomyopathy and improved cardiac responses to PA. In the rat model, dietary DHA reduced mitochondrial oxidative stress in HFD-induced diabetic cardiomyopathy. Dietary DHA reduced mitochondrial oxidative stress and ameliorated PA-induced lipid toxicity. DHA consumption may have had direct effects on cardiovascular risk via myocardial protection.

Verified
Journal Article
Open access
PDF file
FXFangrui Xiu
Fangrui Xiu
Magdalena RauschMagdalena Rausch
Magdalena Rausch
ZGZhi bo Gai
Zhi bo Gai
SSShanshan Su
Shanshan Su
SWShijun Wang
Shijun Wang
MVMichele Visentin
Michele Visentin
Tyrosine kinase inhibitors (TKIs) decisively contributed in revolutionizing the therapeutic approach to cancer, offering non-invasive, tolerable therapies for a better quality of life. Nonetheless, degree and duration of the response to TKI therapy vary depending on cancer molecular features, the ability of developing resistance to the drug, on pharmacokinetic alterations caused by germline variants and unwanted drug–drug interactions at the level of membrane transporters and metabolizing enzymes. A great deal of approved TKIs are inhibitors of the organic cation transporters (OCTs). A handful are also substrates of them. These transporters are polyspecific and highly expressed in normal epithelia, particularly the intestine, liver and kidney, and are, hence, arguably relevant sites of TKI interactions with other OCT substrates. Moreover, OCTs are often repressed in cancer cells and might contribute to the resistance of cancer cells to TKIs. This article reviews the OCT interactions with approved and in-development TKIs reported in vitro and in vivo and critically discusses the potential clinical ramifications thereof.

24 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TGTing Gui
Ting Gui
QCQingfa Chen
Qingfa Chen
JLJiangsong Li
Jiangsong Li
KLKe Lu
Ke Lu
CLChen Li
Chen Li
ZGZhi bo Gai
Zhi bo Gai
Introduction: Chronic kidney disease (CKD) can lead to significant elevation of 1-deoxysphingolipids (1-deoxySL). The increase of 1-deoxySL in turn can result in mitochondrial damage and oxidative stress, which can cause further progression of CKD.Methods: This study assessed the therapeutic effect of Astragaloside IV (AST) against 1-deoxySL-induced cytotoxicity in vitro and in rats with CKD. HK-2 cells were exposed to 1-deoxysphinganine (doxSA) or doxSA + AST. doxSA-induced mitochondrial dysfunction and oxidative stress were evaluated by immunostaining, real-time PCR, oxidative stress sensor, and transmission electron microscopy. The potential effects of AST on kidney damage were evaluated in a rat 5/6 nephrectomy (5/6 Nx) model of CKD.Results: The findings of in vitro experiments showed that doxSA induced mitochondrial damage, oxidative stress, and apoptosis. AST markedly reduced the level of mitochondrial reactive oxygen species, lowered apoptosis, and improved mitochondrial function. In addition, exposure to AST significantly induced the phosphorylation of p62 and the nuclear translocation of Nrf2 as well as its downstream anti-oxidant genes. p62 knock-down fully abolished Nrf2 nuclear translocation in cells after AST treatment. However, p62 knock-down did not affect TBHQ-induced Nrf2 nuclear translocation, indicating that AST can ameliorate doxSA-induced oxidative stress through modulation of p62 phosphorylation and Nrf2 nuclear translocation.Conclusion: The findings indicate that AST can activate Nrf2 antioxidant pathway in a p62 dependent manner. The anti-oxidative stress effect and the further mitochondrial protective effect of AST represent a promising therapeutic strategy for the progression of CKD.

Verified
Journal Article
Open access
PDF file
ZGZhi bo Gai
Zhi bo Gai
SSSophia Samodelov
Sophia Samodelov
IAIrina Alecu
Irina Alecu
THThorsten Hornemann
Thorsten Hornemann
JGJane Grove
Jane Grove
GKGerd A. Kullak-Ublick
Gerd A. Kullak-Ublick
Sphingolipids are exceptionally diverse, comprising hundreds of unique species. The bulk of circulating sphingolipids are synthesized in the liver, thereby plasma sphingolipid profiles represent reliable surrogates of hepatic sphingolipid metabolism and content. As changes in plasma sphingolipid content have been associated to exposure to drugs inducing hepatotoxicity both in vitro and in rodents, in the present study the translatability of the preclinical data was assessed by analyzing the plasma of patients with suspected drug-induced liver injury (DILI) and control subjects. DILI patients, whether intrinsic or idiosyncratic cases, had no alterations in total sphingoid base levels and profile composition compared to controls, whereby cardiovascular disease (CVD) was a confounding factor. Upon exclusion of CVD individuals, elevation of 1-deoxysphingosine (1-deoxySO) in the DILI group emerged. Notably, 1-deoxySO values did not correlate with ALT values. While 1-deoxySO was elevated in all DILI cases, only intrinsic DILI cases concomitantly displayed reduction of select shorter chain sphingoid bases. Significant perturbation of the sphingolipid metabolism observed in this small exploratory clinical study is discussed and put into context, in the consideration that sphingolipids might contribute to the onset and progression of DILI, and that circulating sphingoid bases may function as mechanistic markers to study DILI pathophysiology.

1 February 2025 in Current Drug Metabolism
Verified
Journal Article
Open access
PDF file
JMJingwen Men
Jingwen Men
JLJing Li
Jing Li
TZTianyan Zhang
Tianyan Zhang
YCYang Chen
Yang Chen
BXBin Xu
Bin Xu
ZGZhi bo Gai
Zhi bo Gai
Objective: The clearance of digoxin in obese patients with renal impairment is reduced, leading to elevated serum concentrations and increased risks of digoxin toxicity. However, the exact mechanism of such alterations in obese patients remains unclear. Previous studies have suggested that the organic anion transport-ing polypeptide 4c1 (Oatp4c1, Slco4c1) mediates the elimination of digoxin at the basal membrane of the proximal tubule (PT), indicating its potential role in the pharmacokinetic changes in obese patients. This study aims to investigate the effects of a high-fat diet on digoxin pharmacokinetics and transporter expression in mouse models and further analyze its significance by detecting the expression of transporters in human renal tissue samples. Methods: First, a high-fat diet (HFD)-induced obese mouse model was established. Mice were intraperitone-ally injected with digoxin, and 24-hour urine samples and blood samples at five time points were collected. Pharmacokinetic evaluation was performed using liquid chromatography-tandem mass spectrometry. Renal pathological changes and the expression of digoxin transporters (Oatp4c1 and P-glycoprotein (P-gp)) were assessed using histological staining, Western blots (WB), as well as quantitative polymerase chain reaction (qPCR). Human renal pathologic alterations and expression of transporter proteins showed consistency with the results of animal experiments. To explore the potential use of gadolinium-ethoxybenzyl-diethylenetri-amine-pentaacetic acid (Gd-EOB-DTPA) as a marker for Oatp4c1 function, drug interactions between digoxin and Gd-EOB-DTPA were assessed in mice. Results: HFD-induced obese mice showed significant increases in body weight, blood glucose, and triglycer-ide, along with elevated blood concentration of digoxin, increased areas under the curve, reduced renal clear-ance rate (CLr), and prolonged half-life (t1/2). Histological staining revealed proximal tubular epithelial cell detachment and slight fibrosis in the kidney of the HFD group, with decreased expression of villin, the protein marker for PT. Immunofluorescent staining and Western blots for digoxin transporters showed a significant reduction of Oatp4c1 and P-gp proteins, suggesting that the renal elimination of digoxin was affected solely by the reduced level of Oatp4c1and P-gp proteins. Co-administration of digoxin and Gd-EOB-DTPA resulted in a reduced clearance of Gd-EOB-DTPA, suggesting that both share the same transporter. The blood concen-tration of Gd-EOB-DTPA was higher (77.5%) in the HFD group. Renal magnetic resonance imaging (MRI) intensity was lower in the HFD group after Gd-EOB-DATP administration compared to the Chow group. Conclusion: Obesity-induced kidney damage results in decreased Oatp4c1 and P-gp expression and function in PT, resulting in a reduction of digoxin renal clearance. The inhibition of Gd-EOB-DTPA clearance by digoxin co-administration and the increased Gd-EOB-DTPA blood concentration in the HFD group both sug-gest its potential use in characterizing the Oatp4c1 function in vivo.

1 July 2024 in Journal of Clinical and Nursing Research
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
HGHaoyuan Guo
Haoyuan Guo
JYJing Yu
Jing Yu
ZGZhi bo Gai
Zhi bo Gai
Colorectal cancer used to be a common disease among middle-aged and elderly people. In recent years, the incidence of colorectal cancer (Early-onset colorectal cancer, EOCRC) under 50 years old has increased year by year. Different from the traditional late-onset colon cancer (LOCRC), the diagnosis stage of EOCRC is mostly in the late stage, with poor cell differentiation and poor diagnosis, and there is a layer of consensus and guidance on the diagnosis, treatment or screening of EOCRC at presentation. Therefore, fully understanding the disease characteristics and risk exposure factors of EOCRC is helpful to guide early screening and treatment, which ultimately reduces the mortality of EOCRC. In this review article, we summarized the epidemiology, physiology, risk exposure factors and pathological diagnosis of EOCRC, and discussed the diagnosis and treatment prospect of EOCRC.